RIANA Therapeutics

RIANA Therapeutics


Who we are

RIANA Therapeutics is a spin-off from the University of Veterinary Medicine, Vienna, Austria (Vetmeduni) that is dedicated to developing small molecule therapeutics to disrupt oncogenic protein-protein interactions like STAT5 oligomerization. Our primary focus is on developing a safe and efficacious inhibitor of STAT5, with a particular emphasis on acute myeloid leukemia (AML). This is an area of research that the Moriggl lab has been studying for many years. We are committed to providing novel treatments for this form of cancer, and to advancing our understanding of oncogenic transcription factor oligomerization.

Why/How are we going Green

We recognize that in order to reduce the impact of the laboratory's plastic waste on the climate crisis, it is important that the laboratory implements measures to reduce the amount of plastic produced and disposed of, as well as find ways to recycle and reuse the plastic.

The collaboration between our laboratory and GreenLabs Austria is an important step in helping to reduce our environmental impact and promote sustainability. By recycling plastic materials, we can help reduce our carbon footprint and create a healthier and more sustainable environment.


RIANA Therapeutics